文献速递肝病消化道肿瘤与早癌

活检证实的酒精性肝病患者的癌症风险:一项基于人群的3410人队列研究

Risk of Cancer in Biopsy-Proven Alcohol-Related Liver Disease: A Population-Based Cohort Study of 3410 Persons.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-01-07

该研究纳入瑞典1969-2016年间3410例经肝活检确诊的酒精性肝病患者,与匹配参考人群比较癌症发生风险。结果显示酒精性肝病整体与癌症无显著关联(sHR=1.01),但生存≥1年者风险升高(sHR=1.19),肝细胞癌风险显著增加(sHR=12.80),肝硬化患者10年累积肝细胞癌发生率为5.0%。

要点

  • 酒精性肝病整体癌症风险未显著增加,但生存≥1年者风险升高。
  • 肝细胞癌风险显著增加,sHR达12.80。
  • 肝硬化患者肝细胞癌10年累积发生率为5.0%。

核心结论

  • 活检证实的酒精性肝病患者在诊断后存活超过初期者癌症风险升高,尤其是肝细胞癌。
  • 尽管肝细胞癌风险升高,数据并不支持对酒精性肝病肝硬化患者进行常规肝细胞癌监测具有成本效益。

研究设计与样本

  • 基于人群的队列研究,纳入瑞典1969-2016年间3410例有肝活检的酒精性肝病患者,与匹配参考人群比较。
  • 使用国家登记行政编码和肝活检数据定义暴露与结局,采用竞争风险回归(以非癌死亡为竞争风险)估计亚分布风险比。

主要发现

  • 基线中位年龄58.2岁,67%为男性,2042例(60%)有肝硬化。
  • 酒精性肝病整体与癌症无显著关联(sHR=1.01,95%CI=0.92-1.11)。
  • 生存≥1年者癌症风险升高(sHR=1.19,95%CI=1.08-1.32)。
  • 肝癌风险显著升高(sHR=12.80,95%CI=9.38-17.45)。
  • 肝硬化酒精性肝病患者肝细胞癌发病率为8.6例/1000人年,10年累积发生率为5.0%。

临床怎么用

  • 对酒精性肝病患者应关注癌症风险,尤其是肝癌,但常规肝细胞癌监测的成本效益未被数据支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Persons with alcohol-related liver disease (ALD) are at an increased risk of death and liver-related endpoints, but the association with incident cancer is not well understood, and whether it differs across histopathological subgroups is undefined. METHODS: We investigated the risk of cancer in 3,410 persons with a diagnosis of ALD and an available liver biopsy in Sweden between 1969-2016, compared to a matched reference population. Administrative coding from national registers and liver biopsy data were used to define exposure and outcome status. Competing risk regression, adjusted for available confounders and using non-cancer mortality as the competing risk, was used to estimate subdistribution hazard ratios (sHRs) for incident cancer. RESULTS: At baseline, persons with ALD had a median age of 58.2 years, 67% were men, and 2,042 (60%) had cirrhosis. ALD was not associated with cancer in general (sHR = 1.01, 95%CI = 0.92-1.11), although the risk was increased in persons surviving ≥1 year (sHR = 1.19, 95% CI = 1.08-1.32). The risk of liver cancer was elevated sHR = 12.80, 95%CI = 9.38-17.45). HCC incidence among ALD persons with cirrhosis was 8.6 cases/1,000 person-years, corresponding to a cumulative incidence after 10 years of 5.0%. CONCLUSIONS: Persons with biopsy-proven ALD that survive the initial time after diagnosis are at an elevated risk for cancer, in particular HCC compared with the general population. Although the risk for HCC was elevated, data do not suggest that routine surveillance for HCC in ALD cirrhosis is cost-effective.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Hagström H, Thiele M, Sharma R, et al. Risk of Cancer in Biopsy-Proven Alcohol-Related Liver Disease: A Population-Based Cohort Study of 3410 Persons. Clin Gastroenterol Hepatol. 2021. PMID: 33421629. doi:10.1016/j.cgh.2021.01.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。